1 research outputs found
Supplementary Material for: Presence of Concomitant Systemic Cancer is Not Associated with Worse Functional Long-Term Outcome in Patients with Intracerebral Hemorrhage
<p><b><i>Background:</i></b> Data on clinical characteristics and
outcome of patients with intracerebral hemorrhage (ICH) and concomitant
systemic cancer disease are very limited. <b><i>Methods:</i></b> Nine
hundred and seventy three consecutive primary ICH patients were analyzed
using our prospective institutional registry over a period of 9 years
(2006-2014). We compared clinical and radiological parameters as well as
outcome - scored using the modified Rankin Scale (mRS) and analyzed in a
dichotomized fashion as favorable outcome (mRS = 0-3) and unfavorable
outcome (mRS = 4-6) - of ICH patients with and without cancer. Relevant
imbalances in baseline clinical and radiological characteristics were
adjusted using propensity score (PS) matching. <b><i>Results:</i></b>
Prevalence of systemic cancer among patients with ICH was 8.5% (83/973).
ICH patients with cancer were older (77 [70-82] vs. 72 [63-80] years; <i>p</i> = 0.002), had more often prior renal dysfunction (19/83 [22.9%] vs.107/890 [12.0%]; <i>p</i> = 0.005), and smaller hemorrhage volumes (10.1 [4.8-24.3] vs. 15.3 [5.4-42.9] mL; <i>p</i>
= 0.017). After PS-matching there were no significant differences
neither in mortality nor in functional outcome both at 3 months
(mortality: 33/81 [40.7%] vs. 55/158 [34.8%]; <i>p</i> = 0.368; mRS = 0-3: 28/81 [34.6%] vs. 52/158 [32.9%]; <i>p</i> = 0.797) and 12 months (mortality: 39/78 [50.0%] vs. 70/150 [46.7%]; <i>p</i> = 0.633; mRS = 0-3: 25/78 [32.1%] vs. 53/150 [35.3%]; <i>p</i>
= 0.620) among patients with and without concomitant systemic cancer.
ICH volume tended to be highest in patients with hematooncologic
malignancy and smallest in urothelial cancer. <b><i>Conclusions:</i></b>
Patients with ICH and concomitant systemic cancer on average are older;
however, they show smaller ICH volumes compared to patients without
cancer. Yet, mortality and functional outcome is not different in ICH
patients with and without cancer. Thus, the clinical history or the de
novo diagnosis of concomitant malignancies in ICH patients should not
lead to unjustified treatment restrictions.</p